ES2570135T3 - Sal y solvatos de un derivado de tetrahidroisoquinolina - Google Patents

Sal y solvatos de un derivado de tetrahidroisoquinolina

Info

Publication number
ES2570135T3
ES2570135T3 ES11740973T ES11740973T ES2570135T3 ES 2570135 T3 ES2570135 T3 ES 2570135T3 ES 11740973 T ES11740973 T ES 11740973T ES 11740973 T ES11740973 T ES 11740973T ES 2570135 T3 ES2570135 T3 ES 2570135T3
Authority
ES
Spain
Prior art keywords
solvates
salt
tetrahydroisoquinoline derivative
tetrahydroisoquinoline
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11740973T
Other languages
English (en)
Inventor
Thomas David Mccarthy
Peter Michael Kelly
Craig James Stewart Boyle
Alexander Redvers Eberlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2570135T3 publication Critical patent/ES2570135T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Sal de sodio del ácido (S)-2-(difenilacetil)-1,2,3,4-tetrahidro-6-metoxi-5-(fenilmetoxi)-3-isoquinolin-carboxílico y solvatos del mismo, en forma amorfa o en forma de un solvato cristalino.
ES11740973T 2010-07-21 2011-07-21 Sal y solvatos de un derivado de tetrahidroisoquinolina Active ES2570135T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36636710P 2010-07-21 2010-07-21
PCT/GB2011/001096 WO2012010843A1 (en) 2010-07-21 2011-07-21 Salt and solvates of a tetrahydroisoquinoline derivative

Publications (1)

Publication Number Publication Date
ES2570135T3 true ES2570135T3 (es) 2016-05-17

Family

ID=44386640

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11740973T Active ES2570135T3 (es) 2010-07-21 2011-07-21 Sal y solvatos de un derivado de tetrahidroisoquinolina

Country Status (19)

Country Link
US (3) US8614227B2 (es)
EP (2) EP2595960B1 (es)
JP (3) JP5948326B2 (es)
CN (2) CN103003244B (es)
AU (3) AU2011281381B2 (es)
CA (1) CA2803699C (es)
DK (1) DK2595960T3 (es)
ES (1) ES2570135T3 (es)
HK (1) HK1224290A1 (es)
HR (1) HRP20160540T1 (es)
HU (1) HUE028620T2 (es)
ME (1) ME02407B (es)
NZ (2) NZ605444A (es)
PL (1) PL2595960T3 (es)
PT (1) PT2595960E (es)
SI (1) SI2595960T1 (es)
SM (1) SMT201600171B (es)
WO (1) WO2012010843A1 (es)
ZA (1) ZA201300169B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2595960B1 (en) * 2010-07-21 2016-02-24 Novartis AG Salt and solvates of a tetrahydroisoquinoline derivative
US9320530B2 (en) * 2013-03-13 2016-04-26 The Spectranetics Corporation Assisted cutting balloon
PL3019477T3 (pl) * 2013-07-08 2021-11-22 Novartis Ag Związki heterocykliczne i sposoby ich stosowania
JP6667551B2 (ja) 2015-01-13 2020-03-18 ノバルティス アーゲー アンジオテンシンｉｉ２型拮抗薬としてのピロリジン誘導体
ES2898635T3 (es) 2015-03-12 2022-03-08 Novartis Ag Compuestos heterocíclicos y métodos para su uso
CN106478502B (zh) * 2015-08-29 2021-04-27 上海翰森生物医药科技有限公司 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
EP3475261A1 (en) 2016-06-27 2019-05-01 ratiopharm GmbH Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid
JP2019514862A (ja) * 2017-03-23 2019-06-06 ノバルティス アーゲー （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形
WO2018224037A1 (zh) * 2017-06-09 2018-12-13 南京明德新药研发股份有限公司 作为at2r受体拮抗剂的羧酸衍生物
WO2020012266A1 (en) 2018-07-12 2020-01-16 Novartis Ag Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase
CN112672989A (zh) * 2018-07-12 2021-04-16 科德克希思公司 工程化苯丙氨酸氨裂合酶多肽
CN111620816B (zh) * 2020-05-27 2023-06-02 上海赛默罗生物科技有限公司 螺桨烷类衍生物、其制备方法、药物组合物和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
JP2002504498A (ja) * 1998-02-25 2002-02-12 メルク エンド カムパニー インコーポレーテッド アンギオテンシンｉｉ受容体拮抗薬を用いてｑｔ分散を低下させる、または、ｑｔ分散の進行を阻害する方法
JP4966202B2 (ja) * 2004-12-24 2012-07-04 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 治療または予防のための方法
JP5230595B2 (ja) 2006-03-20 2013-07-10 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド 炎症性疼痛の治療または予防の方法
NZ601383A (en) * 2010-01-19 2014-07-25 Spinifex Pharm Pty Ltd Methods and compositions for improved nerve conduction velocity
EP2595960B1 (en) * 2010-07-21 2016-02-24 Novartis AG Salt and solvates of a tetrahydroisoquinoline derivative

Also Published As

Publication number Publication date
CA2803699A1 (en) 2012-01-26
PT2595960E (pt) 2016-06-02
AU2011281381A1 (en) 2013-01-10
HK1224290A1 (zh) 2017-08-18
HRP20160540T1 (hr) 2016-06-17
JP2016164178A (ja) 2016-09-08
CN105777636A (zh) 2016-07-20
AU2017203236A1 (en) 2017-06-08
HUE028620T2 (en) 2016-12-28
CN103003244B (zh) 2016-04-20
ZA201300169B (en) 2016-03-30
US20150105422A1 (en) 2015-04-16
ME02407B (me) 2016-09-20
WO2012010843A1 (en) 2012-01-26
EP2595960A1 (en) 2013-05-29
SI2595960T1 (sl) 2016-06-30
US9162985B2 (en) 2015-10-20
NZ708529A (en) 2016-11-25
US8614227B2 (en) 2013-12-24
NZ605444A (en) 2015-06-26
DK2595960T3 (en) 2016-05-09
AU2015238774A1 (en) 2015-10-29
US20140080865A1 (en) 2014-03-20
CN103003244A (zh) 2013-03-27
JP2017214415A (ja) 2017-12-07
EP2595960B1 (en) 2016-02-24
AU2011281381B2 (en) 2015-07-16
JP5948326B2 (ja) 2016-07-06
CA2803699C (en) 2016-05-31
EP3081557A1 (en) 2016-10-19
SMT201600171B (it) 2016-07-01
JP2013531057A (ja) 2013-08-01
PL2595960T3 (pl) 2016-09-30
US8927575B2 (en) 2015-01-06
US20120022101A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
ES2570135T3 (es) Sal y solvatos de un derivado de tetrahidroisoquinolina
NO2020018I1 (no) Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
HK1216173A1 (zh) -芳基取代的和 -雜芳基取代的 -羥基吡啶- -基-羰基氨基-鏈烷酸及其衍生物和其鹽，以及用相應 -羥基吡啶甲酸的衍生物進行製備的方法
MX2015017964A (es) Inhibidores de bromodominio.
BR302012001940S1 (pt) "configuração aplicada em para-choque dianteiro"
CR20160099A (es) Formulación de inhibidores de la syk
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
CO6680717A2 (es) Derivados de quinolina y quinoxalina como inhibidores de cinasa
AU2012214029A8 (en) Rorgammat inhibitors
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
HK1211576A1 (en) Salts and solid forms of (s) -3-(4-((4-morpholinomethyl)benzyl)oxy)- 1-oxoisoindolin-2-yl) piperidine-2,6-dione and compositions comprising and methods of using the same (s)-3-(4-((4-()))-1--2-)-26-
SG11201604639YA (en) Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
EP2881384A8 (en) Partially saturated nitrogen-containing heterocyclic compound
MX343160B (es) Dicetopiperazinas para uso en inhibir hiperpermeabilidad vascular.
IT1402907B1 (it) Composizioni topiche per mantenere o ripristinare l'integrita' delle mucose.
IN2014DN10670A (es)
IL223543A (en) Pharmaceutical preparation containing 1– (4– (4– (4,3-dichloro-2 – fluorophenylamino) –7 – methoxyquinazoline – 6 – Iloxy) piperidine – 1 – il) Prof. 2 – an – 1 – on or a common pharmaceutical salt His and an acidic addition
BR302013000613S1 (pt) "configuração aplicada em para-choque dianteiro"
MX2015006223A (es) Composiciones farmaceuticas de inhibidores cetp.
PH12015500012B1 (en) Benzodioxole derivative and preparation method and use thereof
IN2014DN10669A (es)
MY149154A (en) Novel microbiocides
PH12015501146A1 (en) Hydantoin derivative
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
UY35227A (es) ?composiciones herbicidas que comprenden ácido 4-amino-3-cloro-6-(4-cloro-2-fluoro-3-metoxifenil) piridin-2-carboxílico o un derivado de este y flurtamona?.